ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / WAT / insiders
A (72) MTD (78) RVTY (65) AVTR (56) ⌘ Pro Terminal →

Waters Corporation (WAT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$449.53 -2.85% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $448.30

Waters Corporation (WAT) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (59.3% gross margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $45.46B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WAT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Waters Corporation (NYSE: WAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $449.53 (-2.85% 1D, market cap $45.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, WAT ranks #55 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WAT compare to A and MTD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), WAT carries a Roarable B (72/100 RQD), trailing P/E of 73.4x, gross margin of 59.3%, and ROIC of 16.8%. By comparison, A (Agilent Technologies Inc.) holds a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WAT?
▼

Per WAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000697), Waters Corporation generated $3.17B in revenue (+7.0% YoY), $642.6M in net income, and $510.1M in free cash flow against $5.08B in total assets and $947.0M in total debt. Key quantitative strengths: Strong cash generator (59.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $448.32 (-0.27%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 16.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B
Cash (15)Whales (18)SEC (16)Macro (14)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$564 Bull$478 Base$369 Bear
📬 FREE WAT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WAT)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY WAT SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (25% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 15.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$436.61+4.8% Next Q
Q2 (-2Q)
67
Grade B-$457.47+4.2% Next Q
Q3 (-1Q)
69
Grade B-$476.88-5.7% Next Q
Current
72
Grade B$449.53+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the WAT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, WAT faces multiple-compression risk if 73.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 73x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($433.92) or 200D SMA ($370.80) invalidates the momentum regime and cuts Target Base ($477.85) toward Bear Floor ($368.61).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

WAT Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (WAT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on WAT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (WAT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
WAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +48.91%🛡️ HOLDING TREND SUPPORT
2026-11-03O $480.1H $480.1L $449.5C $449.5VOL 1.34M
RES: $488.8SUP: $444.7SMA50: $433.9SMA200: $370.8
$495.1$441.9$388.8$335.6$282.4RES $488.8SUP $444.7$449.52026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WAT Butterfly Map → + Track WAT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
47.3%/yr Implied 5Y Growth

vs. +7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on WAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WAT)

Health Care Rank #55 of 1015 ⚔️ A vs WAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WAT vs. A, MTD, RVTY, AVTR)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Waters Corporation (WAT) ranks #55 by composite RQD confidence (72/100, grade B) and #40 by equity capitalization ($45.46B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with WAT at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WAT ACTIVE
Waters Corporation
B 72/100 73.4x 59.3% 16.8% -2.85% $45.46B Benchmark Subject
A
Agilent Technologies Inc.
B 72/100 39.2x 52.4% 15.3% -1.65% $49.30B /a-vs-wat →
MTD
Mettler-Toledo International Inc.
B+ 78/100 39.6x 59.4% 30.4% +0.20% $33.56B /mtd-vs-wat →
RVTY
Revvity Inc.
C 65/100 76.7x — 3.1% -3.44% $17.52B /rvty-vs-wat →
AVTR
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -2.74% $10.88B /avtr-vs-wat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001000697 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Waters Corporation (WAT) reported GAAP revenue of $3.17B (+7.0% vs. FY2024 revenue of $2.96B , and +7.1% cumulative change since FY2023) , GAAP net income of $642.6M, operating cash flow of $652.6M, and free cash flow of $510.1M (-18.9% YoY). On the balance sheet, WAT closed FY2025 with $5.08B in total assets against $947.0M in total debt (Altman Z-Score: 15.49, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.17B $642.6M $652.6M $510.1M $5.08B $947.0M
FY2024 (FY) 2024-12-31 $2.96B $637.8M $762.1M $629.0M $4.55B $1.63B
FY2023 (FY) 2023-12-31 $2.96B $642.2M $602.8M $469.8M $25.94B $6.07B

3. WAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Waters Corporation (NYSE: WAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $449.53 (-2.85% 1D, market cap $45.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, WAT ranks #55 in composite RQD confidence.

How does WAT compare to A and MTD in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), WAT carries a Roarable B (72/100 RQD), trailing P/E of 73.4x, gross margin of 59.3%, and ROIC of 16.8%. By comparison, A (Agilent Technologies Inc.) holds a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WAT?

Per WAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000697), Waters Corporation generated $3.17B in revenue (+7.0% YoY), $642.6M in net income, and $510.1M in free cash flow against $5.08B in total assets and $947.0M in total debt. Key quantitative strengths: Strong cash generator (59.3% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WAT trading relative to its 50-day, 200-day, and 52-week technical levels?

WAT last traded at $449.53 (-2.85% on volume of 1,943,638 shares), positioning the stock +3.60% above its 50-day simple moving average ($433.92) and +21.23% above its 200-day simple moving average ($370.80). Across its 52-week range of $282.77 to $482.28, WAT sits at the 83.6% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.5% ($420.31 to $478.75).

Direct Sub-Reports: WAT RQD Cockpit WAT 12M Forecast WAT Earnings & Move WAT Dividends & DRIP WAT Insiders & 13F WAT Whale Options WAT Profit Sankey WAT News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

WAT — Waters Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Waters Corporation (WAT) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $449.53 (-2.85% 1D, market capitalization $45.46B).

  • Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 16.8%, gross margin of 59.3%, operating margin of 25.4%, and free cash flow yield of 1.08%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (16/20): Incorporates a 1.02x equity beta, Altman Z-Score of 15.49, Piotroski F-Score of 9/9, and Debt/Equity of 0.37x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Waters Corporation is a NYSE-listed issuer classified under the Health Care sector and the Biotechnology: Laboratory Analytical Instruments industry.. The company reports revenue of $3.17B for FY 2025 and gross margin of 59.3%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Waters Corporation (WAT) reported $3.17B in annual revenue (up from $2.96B in FY2024, +7.0% YoY) and $642.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.96B revenue, $642.2M net income) through FY2025, WAT scaled operating cash flow to $652.6M and free cash flow to $510.1M, backed by $5.08B in total assets against $947.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 72/100): Strong cash generator (59.3% gross margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $282.77 – $482.28 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 73.4x trailing P/E and 51.5x EV/EBITDA against 25.4% operating margins and a 1.02x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Laboratory Analytical Instruments (Health Care), WAT carries a macro regime beta of 1.02 and gross margin of 59.3%.

  • Key Question #1: Can WAT sustain or expand its 25.4% operating margin and 16.8% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.17B and free cash flow of $510.1M, how will capital allocation balance growth reinvestment against $947.0M in total debt?
  • Key Question #3: How sensitive is WAT's 68.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.02x)?

WAT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Waters Corporation (WAT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WAT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WAT Bull vs. Bear Conversation Board — What's Your Call at $449.53?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WAT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on WAT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $596.91 (+29.0%)
📌 Pinned Debate

Institutional accumulation and a 9-of-9 Piotroski F-Score with a 15.49 Altman Z-Score signal strong positioning and financial health.

The street is overcomplicating Waters Corporation (WAT). Institutional accumulation and a 9-of-9 Piotroski F-Score with a 15.49 Altman Z-Score signal strong positioning and financial health.. With an RQD score of 72/100 (B) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $499.74.

CapAlloc_Nerd 🐂 BULL

@ShortSeller_Dan Fair point on 73.4x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (59.3%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $356.29 (-23.0%)
Spot @ $462.72

A P/E (TTM) of 73.4 and EV/EBITDA of 51.5 against a 1.08% FCF yield leave little margin for error if expectations falter.

A P/E (TTM) of 73.4 and EV/EBITDA of 51.5 against a 1.08% FCF yield leave little margin for error if expectations falter.. Look at the math on WAT: paying 73.4x trailing P/E for 16.8% ROIC and 25.4% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $407.19 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%